Dr. Sarah Susan Helgeson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2294 State Route 208 # 7, Montgomery, NY 12549 Phone: 845-778-3591 Fax: 845-255-1201 |
News Archive
Affinium Pharmaceuticals announced today dosing of the first patient in a multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections.
A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes.
Every 67 seconds someone is the United States develops Alzheimer's disease or some form of dementia. It's the sixth leading cause of death in the U.S. and it's the only cause of death in the top 10 in America that cannot be prevented, cured or slowed. This month, as the nation observes "Alzheimer's & Brain Awareness Month," James E. Galvin, M.D., M.P.H., one of the most prominent neuroscientists in the country, is at the helm of cutting-edge research, screening methods and clinical care for all forms of dementia and cognitive impairments as well as neurodegenerative diseases like Alzheimer's disease and Parkinson's disease.
Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as 'exciting' and a 'very promising therapy' in an editorial published in Neuro-Oncology, the leading journal of the Society of Neuro-Oncology.
› Verified 3 days ago